REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

A Research on the Therapeutic Potential of Novel Chemical Entities Utilized in an Animal Model of Alzheimer's Disease

Dr. Sailesh Narayan[1], Dr. Barun Ranjan Sarkar[2], Dr. Dashrath Singh[3], Dr. Suraj Sharma[4]

[1]Associate Professor, Department of Pharmacy, Usha Martin University, Ranchi- Jharkhand
[2]Assistant Professor, Department of Pharmacy, Himalayan University, Itanagar-Arunachal Pradesh
[3]Professor, Department of Pharmacy, Mangalayatan University, Aligarh, Uttar Pradesh
[4]Associate Professor, Collage of Pharmacy, Sikkim Professional University, Gangtok, Sikkim

ABSTRACT

Alzheimer's disease is a debilitating condition that affects the nervous system. The current method of treating Alzheimer's diseaseis ineffective at achieving long-term control of the disease and is also associated with a variety of side effects, such as dyskinesia. The development of non-dopaminergic treatments for Alzheimer's disease(AD) is aimed at creating therapies that can improve motor deficits without the risk of the adverse chronic effects that are associated with traditional dopaminergic medications. The metabotropic glutamate receptor mGluR4, which is currently receiving attention, is one example of such a target. The activation of mGluR4 has the potential to be presented as a novel and promising treatment for Parkinson's disease. In addition, it is believed that a valid and viable treatment option for Alzheimer's diseaseis the application of a positive allosteric modulator at the orthosteric glutamate site as opposed to the use of direct acting agonists.

Keywords TAS-4, Alzheimer's disease patients, toxicity, standard dopaminergic drugs

Introduction:

In this study, we present the pharmacological characterization of the N-(2, 4-dichlorophenyl) pyridine-2-carboxamide, a mGluR4 PAM (TAS-4),which was performed on several different rodent models of AD. TAS-4 are highly selective and potent mGluR4 PAMs that target the human mGluR4 receptor (EC50-287.8 nm.). In studies with C57BL/6 mice and Wistar rats, TAS-4 exhibited a favorable pharmacokinetic profile. The effectiveness of TAS-4 was demonstrated whether it was given by itself or TAS-4 proved successful in reversing analgesic properties hallucinations and delusions when combined with L-DOPA. when it was administered on its own. Moreover, intraperitoneal administration of an L-3, 4-dihydroxyphenylalanine threshold dosage (L-DOPA, 4 mg/kg) potentiated posterolateral turning actions induced by acute TAS-4. In the bilateral high dose rat model of Vascular dementia, this is a standard procedure for antiparkinson medication screening. In another acute test, TAS-4 (10 mg/kg i.p.) + L-DOPA (4 mg/kg i.p.) demonstrated turning behaviour that was comparable to that observed with L-DOPA (8 mg/kg i.p.) in a unilateral 6-OHDA rat model. Treatment of animals with TAS-4 (10 mg/kg i.p.) as well as L-DOPA (4 mg/kg i.p.) for a prolonged period of time (28 days, twice a day) did not result in Over the duration of the experiment, the mice became more sensitive to trying to turn actions as well as strange, uncontrollable shaking.

When used as a treatment, A completely effective mg dosage of L-DOPA given over a long period of time (8 mg/kg intraperitoneally) was found to significantly make people aware of trying to turn behaviour as well as strange, uncontrollable moves in a study on dyskinesia. In

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

an MPTP-induced mouse model, TAS-4 demonstrated a neuroprotective effect that was dose dependent. In the MPTP-induced mouse model of Parkinson's disease, oral administration of TAS-4 (30 mg/kg, p.o., b.i.d.) for 21 days made a big difference. in motor coordination on the rotarod as well as an improvement in grip strength. TAS-4 (30 mg/kg, orally, twice daily) not only significantly decreased the level of IL-6 in the mice's striatum that had been MPTP was used to treat, but it also significantly attenuated the degree to which dopamine was depleted. TAS-4 was found to play a protective role in the neuroinflammation that was caused by lipopolysaccharides. When compared with disease control, TAS-4 (10 and 30 mg/kg, given orally) demonstrated a statistically significant reduction in the level of striatal IL-6.

According to these findings, TAS-4, when combined with just a little L-DOPA, exhibited activity against Parkinson's comparable to whatever a filled dosages of L-DOPA does. This was accomplished instead of making the engine adverse effects worse like abnormal involuntary movements. Furthermore, In the animal model of Alzheimer's disease, TAS-4 guards against MPTP-induced damage in dopaminergic neurons (AD).

TAS-4 has the potential to be a novel non-dopaminergic therapy for the treatment of Alzheimer’s diseasepatients. This therapy has the potential benefit of not just treating the symptoms of the condition, but also the potential benefit of offering promise in preventing neuronal cells from any further degeneration.. This would be accomplished without the liability for the adverse chronic effects that are associated with the use of standard dopaminergic drugs.

Background

The natural, regular, or synthetic substances that are used for medicinal purposes are referred to as drugs. Despite the fact that the repeated use of some of these substances can lead to temporary or chronic dependency, drugs are used for medicinal purposes. Synthetic drugs, in contrast to naturally occurring drugs, are produced through a chemical process in a research facility. The purpose of these medications is to subtly alter the atomic structure of the substance in order to circumvent the laws that are currently in place regarding medication.

The anticancer drugs cisplatin, amifostine, mesna, and dexrazoxane, amongst others, are generally recommended for use in chemotherapy for disease patients, despite the fact that they are associated with extremely toxic properties. There are certain patients who are more likely to experience drug-induced toxicity, as well as certain clinical settings in which this phenomenon is more likely to occur. It is necessary for it to support the use of chemoprotective drugs so that harmful effects caused by synthetic drugs can be avoided. As a result, it is anticipated that new medications will be developed that can neutralise the potentially fatal effects of cisplatin.

LR

Bibi et al. (2018) investigated the antibacterial and antifungal activity of four different plants by using the agar well diffusion method as well as the agar tube dilution method (Cuscutareflexa, Cedrela serrata, Hedera nepalensis, and Hedera helix). The plants were put

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

through a series of tests to determine their capacity to stop the spread of bacteria and fungi. Plants of the species Cuscutareflexa, Performance. Performance serrata, Hedera nepalensis, and Hedera helix were utilised in this study. For the purpose of determining whether or not antibacterial and antifungal properties are present, the following species were utilised: two gram-positive (S. aureus and Streptococcus pyogenes), three gram-negative (K. pneumoniae, Pseudomonas fluorescens, and E. coli), and two fungal pathogens (Fusarium oxysporum and Penicillium sp). According to the findings, the amount of inhibition against Klebsiella pneumonia that was detected in the methanol extract and chloroform extracts of Cuscutareflexa was the greatest among all of the tested substances. In the instance of the fungal isolates, the extract of Hedera helical in formaldehyde demonstrated the greatest amount of inhibition versus F. oxysporum.

Objective

The following are the aims and objectives of the current investigation:

- To evaluate the in-vitro potency of mGluR 4 PAMs in Tests for Calcium Mobilizationusing mGluR4/Gqi5/Chinese Hamster Ovary Cells. mGluR4 stands for mGluR4/Chinese hamster ovarian cells Gqi5
- To Determine the Degree of Selectivity Exhibited by TAS-4 in Relation to Other mGluR Receptors
- To determine the acute oral toxicity of TAS-4 in female Wistar rats and to scale up production of the compound.

Hypothesis

- H0. There is no significant change in the in-vitro potency of mGluR 4 PAMs in Tests for Calcium Mobilization using mGluR4/Gqi5/Chinese Hamster Ovary Cells. mGluR4 stands for mGluR4/Chinese hamster ovarian cells Gqi5
- H1. Tere is significant change in the in-vitro potency of mGluR 4 PAMs in Tests for Calcium Mobilization using mGluR4/Gqi5/Chinese Hamster Ovary Cells. mGluR4 stands for mGluR4/Chinese hamster ovarian cells Gqi5
- H0. There is no significant change the Degree of Selectivity Exhibited by TAS-4 in Relation to Other mGluR Receptors
- H2. There is significant change in the Degree of Selectivity Exhibited by TAS-4 in Relation to Other mGluR Receptors
- H0. There is no significant change in the acute oral toxicity of TAS-4 in female Wistar rats and to scale up production of the compound.
- H3. There is significant change in the acute oral toxicity of TAS-4 in female Wistar rats and to scale up production of the compound.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

Material and Method:

Study design

Calcium Mobilization Test Results Based on the Functional Efficacy of Test Compounds

50,000 human mGluR4/Gqi5/Chinese hamster ovary cells were seeded into each well of a 96-well black-walled, clear-bottomed tissue culture plate (Greiner Bio-One, Monroe, North Carolina) containing DMEM with 10% FBS, penicillin and streptomycin at a concentration of 100 units/ml, and sodium pyruvate at a concentration of 1 mM (plating medium). Overnight, the cells were grown in culture at a temperature of 37 degrees Celsius with a carbon dioxide concentration of 5%. The medium was withdrawn the next day and 20 l of 1 M Fluo-4 AM was substituted (Life Technologies F-14201),It was made into a stock solution of 1 mM in DMSO before being used. An experiment buffer (Aspect of having' sterile saline liquid) was then used to dilute the solution., 1% BSA, 30 min at 37 degrees Fahrenheit with 2.5 mM etc was (Sigma). after being combined in a ratio of 1:1 with 10percentage points (w/v) of a pluronic acid called F-127. After removing the dye, 100 l of the assay buffer was added in its place. Using a calcium assay in which the cells express to connect mGlu4 to ca mobilisation, the recombinant G enzyme Gqi5 was used, the potency of all of the test compounds was determined by performing concentration-response curves (CRCs, 9 points, ranging from approximately 10 M-1 nM at 0.5% final DMSO concentration). These CRCs covered a range of approximately 1 nM at a final concentration of 0.5% DMSO. Ca2+ flux was measured by using Flex station III (Molecular devices) of a fluorescence baseline for 15s (excitation, 488 nm; emission, 535 210 nm), 5X of stock of compounds was made so that 20 l of the cells received substances. Ca2+ flux is assessed using a fluorescence baseline.

After 15 seconds, the glutamate was added automatically by the machine.

Fluorescence of calcium was measured as a fold increase over the baseline value, and the raw data were then normalised to the level of response that was greatest to glutamate. Compounds' potency, as measured by EC50, and maximum response, as expressed as a percentage of Glu maximum, were calculated with the help of Version Prism's 4 logistic solution 5.0. (Le Poul et al., 2012).

Data collection and data analysis

This research is both descriptive and experimental. Following the design of the study, the researcher moves on to the management and collecting of data. Following the collection of data, the researcher will investigate and employ descriptive research.

Primary Data Collection

The primary source is where the researcher gets first-hand knowledge or original facts about a subject. When referring to in-vivo studies, the values are presented as a Mean with a Standard Error of the Mean for each group.

In order to determine whether or not the results were statistically significant, a one-way analysis of variance (ANOVA) was performed, and then Dunnett's test was performed. If the

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

p value was less than 0.05, then it was considered to be significant. Graph Pad Prism version 5.0 was utilised throughout each and every statistical analysis that was carried out.

Secondary Data Collection

The secondary data will be gathered by the researcher through articles, newspapers, and the Internet. This is a small but equally important component of the research. For this area, information will be acquired from websites, journals, books, published articles, and corporate documents. This type of information has been obtained and recorded by other persons or organizations, sometimes for completely unconnected reasons.

Result

Calcium Mobilization Test Results Based on the Functional Efficacy of Test Compounds

In a calcium mobilisation assay, the functional activity of all five compounds (TAS-1, TAS-2, TAS-3, TAS-4, and TAS-5) at mGluR4 was evaluated. These cells coexpressed human mGluR4 Using the chimeric G protein known as Gqi5, which is responsible for establishing the connection between the Gi/occupied mGluR4 receptor and the phospholipase C/Ca2+ pathway. In a certain way, the response to a glutamate concentration of EC20 was potentiated that was dependent on the concentration of each of the five compounds that were tested (TAS-1, TAS-2, TAS-3, TAS-4, and TAS-5). The response to an EC20 concentration of glutamate produced by TAS-1 was potentiated in a way that is dependent on concentration, with a value of 2481.0 nM for the EC50. In comparison to TAS-1, TAS-2 was able to potentiate the reaction to an EC20 level of glutamate with such a potent Ic50 values ranging of producing a density enhancement of the response 1190.0.0 nM.. In comparison to TAS-1 and TAS-2, TAS-3 potentiated the reaction to an EC20 level of glutamate with such a potent Ic50 values ranging of producing a density enhancement of the response. 983.6 nM. When compared with TAS1, TAS-2, TAS-3, and TAS-5, TAS-4 potentiated the reaction to an EC20 level of glutamate with such a potent Ic50 values ranging of producing a density enhancement of the response 287.8 nM. This was in contrast to TAS1, TAS-2, TAS-3, and TAS-5, all of which produced a less potent response. The response to an EC20 concentration of glutamate was potentiated by TAS-5, which had a potent EC50 value of 1725.0 nM. This potentiation was concentration-dependent.

TAS-4 was discovered to be the most powerful compound out of all five compounds; this could be due to the presence of an N-2, 4-dichloro phenyl group in TAS-4, which will be used for additional research.

Discussion:

The loss of dopamine - producing basal ganglia (SNc), that also supplies a significant dopamine receptor nerve fibers to a forebrain as well as other dorsal o`clock (BG) atoms, is the cause of Vascular dementia, which is a neurological conditionthat progresses over time and is known as a chronic condition. Dopamine-replacement therapies can be helpful in the

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 23, No. 4 (2022)
http://www.veterinaria.org
Article Received: 20 August 2022; Revised: 28 October 2022; Accepted: 05 November 2022

early stages of the disease; however, the efficacy of these treatments typically declines as the disease advances, and they are associated with a large number of adverse effects that put a limit on the dose, such as oscillations on and off, involuntary movements, or cognitive deficits. Despite their early promise, dopamine-replacement therapies are not a cure for Alzheimer's disease(Park et. al., 2015).

Conclusion:

In conclusion, the results of our research indicate that TAS-4 may be a powerful and selective mGluR4 PAM that demonstrates tremendous therapeutic potential in animal studies of Alzheimer's diseaseas it is given as conjunction to L-DOPA. Our findings show that this highly selective mGluR4 PAM is effective in rodent models of Parkinson's disease, and when combined with L-DOPA, there is a decreased risk of dyskinesias occurring. In addition, TAS-4, when combined with a threshold dose of L-DOPA, has the potential to treat the symptoms of Alzheimer's diseasewithout causing dyskinesias to develop. TAS-4 also demonstrated a neuroprotective role in the MPTP mouse model, suggesting that it may also show promise in the protection of dopaminergic neurons.

TAS-4 can be a novel non-dopaminergic therapy for the treatment of patients with Parkinson's disease. This therapy has the potential benefit of not just treating the symptoms of the condition, but also the potential benefit of offering promise in preventing neuronal cells from any further degeneration. This can be accomplished without the liability for the adverse chronic effects connected to the use of common dopaminergic medications.

References:

[1]. Le Poul E, Boléa C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser J, Hodge M, Smith M, DiLella G, Liverton N, Hess F, Browne E, Reynolds J. A Potent and Selective Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator Improves Movement in Rodent Models of Parkinson's disease. J Pharma Eex Thera 2012: 343: 167–177

[2]. Park A, Stacy M. Disease-Modifying Drugs in Parkinson's Disease. Drugs 2015 ; 75: 2065-2071

[3]. Brooks I, Chadwick A, Gelbard A, Cory-Slechta A, Federoff J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999; 823: 1-10.

[4]. Cacabelos R. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci 2017;4: 18(3)

[5]. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011; 164: 1357-1391.